Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 1
1975 2
1977 1
1978 2
1979 2
1980 1
1981 1
1982 1
1983 1
1984 3
1986 1
1987 1
1988 3
1990 1
1991 2
1992 1
1993 2
1995 2
1996 1
1999 3
2000 3
2001 2
2002 1
2003 1
2004 1
2006 1
2007 1
2010 1
2011 3
2012 1
2013 3
2014 2
2015 3
2016 1
2017 2
2018 3
2019 1
2020 9
2021 6
2022 9
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives S, Schmiegelow K, Silverman LB, Stary J, Vora A, Brown P. Buchmann S, et al. Blood. 2022 Mar 24;139(12):1785-1793. doi: 10.1182/blood.2021012328. Blood. 2022. PMID: 34192312 Free PMC article.
Relapse can only be defined in patients who have achieved CR and must include a specific threshold of leukemic cells in the bone marrow confirmed by MRD, the detection of central nervous system leukemia, or documentation of extramedullary disease. ...
Relapse can only be defined in patients who have achieved CR and must include a specific threshold of leukemic cells in the bone marrow conf …
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Shen S, et al. JAMA Oncol. 2020 Mar 1;6(3):358-366. doi: 10.1001/jamaoncol.2019.5868. JAMA Oncol. 2020. PMID: 31944221 Free PMC article. Clinical Trial.
CONCLUSIONS AND RELEVANCE: Intensive chemotherapy including dasatinib at a dosage of 80 mg/m2 per day yielded superior results in the treatment of Philadelphia chromosome-positive ALL compared with imatinib mesylate at a dosage of 300 mg/m2 per day and provided excellent control …
CONCLUSIONS AND RELEVANCE: Intensive chemotherapy including dasatinib at a dosage of 80 mg/m2 per day yielded superior results in the treatm …
Central nervous system lymphoma.
Lister A, Abrey LE, Sandlund JT. Lister A, et al. Hematology Am Soc Hematol Educ Program. 2002:283-96. doi: 10.1182/asheducation-2002.1.283. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446428 Review.
John Sandlund reviews the success of sequential clinical trials of overall therapy for acute lymphoblastic leukemia in childhood, identifying those patients at high risk of central nervous system leukemia and the development of a rational therapeutic s …
John Sandlund reviews the success of sequential clinical trials of overall therapy for acute lymphoblastic leukemia in childhood, identifyin …
Central nervous system leukemia.
Bleyer WA. Bleyer WA. Pediatr Clin North Am. 1988 Aug;35(4):789-814. doi: 10.1016/s0031-3955(16)36510-5. Pediatr Clin North Am. 1988. PMID: 3047654 Review.
Prognostic factors for clinical outcomes of patients with central nervous system leukemia.
Bharucha J, Cao Q, Sachs Z, Smith A, Williams S, Amin K, Bachanova V, Warlick E, Brunstein C, Weisdorf D, Bejanyan N. Bharucha J, et al. Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):240-245. doi: 10.1016/j.hemonc.2020.11.004. Epub 2020 Nov 24. Hematol Oncol Stem Cell Ther. 2021. PMID: 33271117 Free PMC article. Clinical Trial.
Comprehensive craniospinal radiation for controlling central nervous system leukemia.
Walker GV, Shihadeh F, Kantarjian H, Allen P, Rondon G, Kebriaei P, O'Brien S, Kedir A, Said M, Grant JD, Thomas DA, Gidley PW, Arzu I, Pinnix C, Reed V, Dabaja BS. Walker GV, et al. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1119-25. doi: 10.1016/j.ijrobp.2014.08.004. Int J Radiat Oncol Biol Phys. 2014. PMID: 25539370 Free PMC article.
Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB, Zhang X, Guo ZW, Liu MM, Xu N, Huang F, Fan ZP, Xuan L, Deng L, Lin SH, Xu J, Sun J, Liu QF. He JB, et al. Int J Cancer. 2020 Aug 15;147(4):1071-1077. doi: 10.1002/ijc.32817. Epub 2019 Dec 19. Int J Cancer. 2020. PMID: 31785158 Free article.
Central nervous system leukemia (CNSL) relapse is relatively common among Philadelphia chromosome-positive (Ph+) leukemia patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). ...
Central nervous system leukemia (CNSL) relapse is relatively common among Philadelphia chromosome-positive (Ph+) …
85 results